CoChat

Implications of weight gain with newer anti-retrovirals: 10-year predictions of cardiovascular disease and diabetes

The DOI matches its Crossref record; 53 of the 53 references it cites were found in a registry or an index.

Abstract

OBJECTIVE: To evaluate the long-term risks of type 2 diabetes mellitus (T2DM) and cardiovascular disease (CVD) secondary to weight gain and clinical obesity associated with the initiation of integrase strand transfer inhibitors and tenofovir alafenamide (TAF) in the ADVANCE trial using validated risk equation tools. DESIGN: Retrospective data analysis. METHODS: In ADVANCE, 1053 treatment-naive participants in South Africa (99% black, 59% female) were randomized to 96 weeks of TAF/emtricitabine + dolutegravir (TAF/FTC + DTG), tenofovir disoproxil fumarate/FTC + DTG (TDF/FTC + DTG), or TDF/FTC + efavirenz (TDF/FTC/EFV). The 5 and 10-year risks of CVD were calculated using D:A:D, QRISK and Framingham, and T2DM risk using QDiabetes, Cambridge Diabetes and Leicester Practice Risk scores. Participants were included in this analysis if they were above 30 years old at baseline. RESULTS: A total of 217 (TAF/FTC + DTG), 218 (TDF/FTC + DTG), and 215 (TDF/FTC/EFV) participants had 96-week data available. Weight gain was +8.1, +4.2, and +2.4 kg on TAF/FTC + DTG, TDF/FTC + DTG, and TDF/FTC/EFV, respectively. Participants on TAF/FTC + DTG had greatest risk scores for CVD (using QRISK) and T2DM, driven by weight changes. Differences were statistically significant between TAF/FTC + DTG and TDF/FTC/EFV for CVD risk using the QRISK equation, equivalent to one extra case per 1000 people treated over 10 years, and between all treatment groups for T2DM risk. Six extra T2DM cases were predicted on TAF/FTC + DTG vs. TDF/FTC + DTG using QDiabetes. CONCLUSION: Obesity, especially with TAF/FTC + DTG, drove increased risk of T2DM, with some evidence of greater CVD risk. However, predictive tools have not been validated in the HIV-positive and black African population.

Overview

Integrity signals

Registry

Crossref · 10.1097/qad.0000000000002930

Cites

53 of 53 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Citations

Cites

Show all 53 references

Cited by

See all 81

Metadata

Authors
McCann, K., Shah, S., Hindley, L., Hill, A., Qavi, A., Simmons, B., Serenata, C., Sokhela, S., & Venter, W. D. F.
Affiliations
  • Imperial College London (GB)
  • University of Liverpool (GB)
  • University of the Witwatersrand (ZA)
  • Ezintsha, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
Corresponding author
  • McCann, Kaitlyn
  • Shah, Shahini
Venue
AIDS
Published
2021-04-28
Volume
35
Issue
10
Pages
1657-1665
ISSN
  • 0269-9370 (ISSN-L)
  • 1473-5571
OpenAlex
W3158467183
Cited by
72
References
53
Citations by year
2026: 5 · 2025: 10 · 2024: 17 · 2023: 22 · 2022: 12 · 2021: 6
FWCI
14.89
Type
journal article
Language
en
Open access
closed
Locations
  • AIDS (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Infectious Diseases › HIV-related health complications and treatments
  • Health Sciences › Medicine › Infectious Diseases › HIV/AIDS drug development and treatment
  • Health Sciences › Medicine › Infectious Diseases › HIV/AIDS Research and Interventions
Keywords
weight gain, tenofovir alafenamide, tenofovir disoproxil fumarate, integrase strand transfer inhibitors, dolutegravir, efavirenz, HIV, type 2 diabetes, cardiovascular disease, obesity, cardiovascular risk prediction, diabetes risk prediction, ADVANCE trial, Black African population, antiretroviral-naive patients
MeSH terms
Emtricitabine, Adult, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Female, Humans, Male, Retrospective Studies, South Africa, Weight Gain, HIV Infections, Anti-HIV Agents

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Implications of weight gain with newer anti-retrovirals: 10-year predictions of cardiovascular disease and diabetes. https://app.cochat.ai/papers/10.1097/qad.0000000000002930
The paper
McCann, K., Shah, S., Hindley, L., Hill, A., Qavi, A., Simmons, B., Serenata, C., Sokhela, S., & Venter, W. D. F. (2021). Implications of weight gain with newer anti-retrovirals: 10-year predictions of cardiovascular disease and diabetes. AIDS. https://doi.org/10.1097/qad.0000000000002930

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.